DGAP-News: GEA Group Aktiengesellschaft
/ Key word(s): Miscellaneous/Incoming Orders
GEA wins one of the largest orders in the company's history in the growing "New Food" market of the future - Biotechnology customer Novozymes chooses GEA technology for a new functional protein plant in Nebraska, USA - Order value well into the high double-digit million-euro range
"The demand for foods that have a demonstrably lower environmental footprint than conventionally produced products is growing enormously," says GEA CEO Stefan Klebert. "With our technologies and experience in scaling industrial applications, GEA is ideally positioned to serve the new food market and thus contribute to our corporate purpose of 'engineering for a better world'," says Klebert. "We are pleased to partner with Novozymes in this strategic project." For decades, Novozymes has been developing fermented catalytic (i.e. industrially produced) proteins - enzymes - that are the basis for many industrial applications. Only recently, the company announced its intention to invest DKK 2 billion in the growth market for functional proteins (advanced protein solutions) for the food industry. "This investment in a new, state-of-the-art production line in Blair, Nebraska, underscores our commitment to feeding the world sustainably and demonstrating the true strength of biotechnology," says COO & Executive Vice President Graziela Chaluppe dos Santos Malucelli, Novozymes. The new plant covers the manufacturing steps from harvesting to separation of proteins. According to Heinz-Jürgen Kroner, Senior Vice President Liquid Technologies at GEA and responsible for the company's alternative foods business, both partners are united by their ability to build scalable, reliable, and highly efficient plant systems. "This project is exceptional in many respects. The intensive bidding phase saw us planning the production lines for the ingredients less than a year later. We now aim to implement the project at the same pace. The partnership is a very rewarding experience." GEA will now construct the process systems, which include membrane filters, mixers, homogenizers, heat exchangers, pasteurizers and UHT units, cleaning and filling systems as well as the pump and valve technology. Installation will start mid-2022. The production capacity initially built can easily be expanded to multiply the capacity in the future as demand grows. About GEA GEA is listed in the German MDAX and the STOXX(R) Europe 600 Index and is also among the companies comprising the DAX 50 ESG and MSCI Global Sustainability Indices. More information can be found online at www.gea.com About Novozymes
Contact: GEA Group Aktiengesellschaft Phone +49 (0)211 9136 1081 Fax +49 (0)211 9136 31087 gea.com Additional features: File: GEA will build Novozymes' new plant to produce alternative products for the human nutrition turnkey. This order in the growing 'New Food' market is one of the largest orders in GEA's history.
16.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | GEA Group Aktiengesellschaft |
Peter-Müller-Straße 12 | |
40468 Düsseldorf | |
Germany | |
Phone: | +49 (0)211 9136-0 |
Fax: | +49 (0)211 9136-31087 |
E-mail: | ir@gea.com |
Internet: | www.gea.com |
ISIN: | DE0006602006 |
WKN: | 660200 |
Indices: | MDAX |
Listed: | Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Munich; Regulated Unofficial Market in Hanover, Stuttgart, Tradegate Exchange |
EQS News ID: | 1233801 |
End of News | DGAP News Service |
|
1233801 16.09.2021